FindTrial
Sign In

A 4-month Treatment, Randomized, Double-blind, Placebo-Controlled, Multi-centre, Parallel-Group Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of Different Dosing Regimens of AZD1656 as Monotherapy in Japanese Type 2 Diabetes Mellitus Patients

A 4-month Treatment, Randomized, Double-blind, Placebo-Controlled, Multi-centre, Parallel-Group Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of Different Dosing Regimens of AZD1656 as Monotherapy in Japanese Type 2 Diabetes Mellitus Patients

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221154
Enrollment
Unknown
Registered
2010-07-08
Start date
2010-07-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

investigational material(s) Generic name etc : AZD1656 INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : O

Sponsors

AstraZeneca
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - women of non-childbearing potential. - Provision of informed consent prior to any study specific procedures - Nailve T2DM patients with HbA1c 7.5% or more but 10% or less, or T2DM Patients treated with one or two oral anti-hyperglycaemic agent(s) with HbA1c 7.5% or more but 9.5% or less at enrolment visit (Visit1)

Exclusion criteria

Exclusion criteria: - Clinically relevant medical history or concurrent disease such as cardiovascular disease, renal disease, hepatic disease and haematological disease. - The investigator(s) judged that the Subject should not participate in the study according to screening test or medical history. - Participation in another clinical trial and/or intake of another investigational drug within the last 30 days prior to enrolment visit

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026